MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
24.49
+1.33 (5.74%)
Sep 26, 2024, 4:00 PM EDT - Market closed
MBX Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Selling, General & Admin | 8.86 | 6.98 | 3.86 |
| Research & Development | 42.05 | 28.33 | 21.3 |
| Operating Expenses | 50.91 | 35.31 | 25.16 |
| Operating Income | -50.91 | -35.31 | -25.16 |
| Interest Expense | - | - | -0.37 |
| Interest & Investment Income | 2.67 | 1.7 | 0.35 |
| Other Non Operating Income (Expenses) | - | - | -0.07 |
| EBT Excluding Unusual Items | -48.24 | -33.61 | -25.26 |
| Gain (Loss) on Sale of Investments | 1.04 | 1.04 | 0.03 |
| Other Unusual Items | - | - | -0.9 |
| Pretax Income | -47.2 | -32.56 | -26.14 |
| Net Income | -47.2 | -32.56 | -26.14 |
| Net Income to Common | -47.2 | -32.56 | -26.14 |
| Shares Outstanding (Basic) | 14 | 12 | 8 |
| Shares Outstanding (Diluted) | 14 | 12 | 8 |
| Shares Change (YoY) | - | 52.73% | - |
| EPS (Basic) | -3.35 | -2.66 | -3.26 |
| EPS (Diluted) | -3.35 | -2.66 | -3.26 |
| Free Cash Flow | -43.65 | -32.11 | -23.56 |
| Free Cash Flow Per Share | -3.10 | -2.62 | -2.94 |
| EBITDA | -50.72 | -35.15 | -25.11 |
| D&A For EBITDA | 0.19 | 0.16 | 0.06 |
| EBIT | -50.91 | -35.31 | -25.16 |
Source: S&P Capital IQ. Standard template.
Financial Sources.